Premium Fezolinetant API in Pakistan: Reliable Raw Material Supply for Pharmaceutical Formulators

Product Name: Fezolinetant (Active Pharmaceutical Ingredient)

Supplier / Distributor: Morgan

Therapeutic Category: Neurokinin 3 (NK3) Receptor Antagonist

Indications: Vasomotor Symptoms (VMS) associated with Menopause

Compliance Notice: This technical data page is strictly for B2B pharmaceutical manufacturers, contract manufacturing organizations (CMOs), and analytical laboratories. The Fezolinetant distributed by Morgan is a highly purified Active Pharmaceutical Ingredient (API) intended exclusively for commercial formulation and laboratory R&D. It is not a finished drug product.

About Morgan: Morgan Chemicals (Pvt.) Ltd. is a pharmaceutical raw material trading and distribution company. We source APIs from DRAP-registered and internationally certified manufacturers and supply exclusively to licensed pharmaceutical companies, CMOs, and research facilities. We do not manufacture APIs or sell finished medicines.

Product Overview and Mechanism of Action

Fezolinetant is a first-in-class, non-hormonal, small-molecule Active Pharmaceutical Ingredient (API). In neuroendocrinology and women's health pharmacology, it is classified as a selective neurokinin 3 (NK3) receptor antagonist. For pharmaceutical manufacturers expanding their gynecological and menopausal care portfolios, this API represents a major therapeutic shift, offering a targeted non-hormonal alternative for managing vasomotor symptoms (VMS), commonly known as hot flashes and night sweats.

The pharmacological mechanism of Fezolinetant is highly specific to the central nervous system, specifically the thermoregulatory center located in the hypothalamus. Body temperature is regulated by kisspeptin/neurokinin B/dynorphin (KNDy) neurons. Under normal physiological conditions, estrogen provides negative feedback to these neurons, maintaining thermoregulatory balance.

During menopause, the significant decline in estrogen levels removes this inhibitory feedback. This leads to the hypertrophy and overactivity of KNDy neurons, driven by the uninhibited signaling of neurokinin B (NKB). Fezolinetant functions by competitively binding to and blocking the NK3 receptor on these neurons. By inhibiting NKB binding, this API restores the balance in the hypothalamic thermoregulatory center, directly mitigating the frequency and severity of vasomotor symptoms.

For pharmaceutical formulation scientists, integrating this API allows for the development of oral solid therapeutics tailored for women who either have contraindications to hormone replacement therapy (HRT) or prefer a non-hormonal treatment pathway. In commercial manufacturing, Fezolinetant is typically formulated into 45 mg immediate-release oral tablets.

Sourcing Fezolinetant in Pakistan: Morgan’s Supply Network

Developing and commercializing novel non-hormonal formulations requires a highly traceable and resilient raw material pipeline. Procuring first-in-class specialty APIs for local commercial manufacturing frequently involves navigating extended lead times, stringent customs bottlenecks, and complex regulatory compliance. Sourcing Fezolinetant Pakistan through Morgan’s localized distribution network systematically mitigates these supply chain variables.

Morgan sources commercial-scale and pilot-scale quantities from global manufacturing partners operating in strict adherence to ICH Q7 Good Manufacturing Practice (GMP) guidelines. Partnering with Morgan as your primary API vendor secures several operational provisions for your manufacturing facility:

• DRAP Registration Support: Morgan facilitates the secure transfer of the necessary regulatory documentation required for local compliance. This includes the open part of the Drug Master File (DMF), comprehensive impurity profiles, and accelerated stability data to strictly support your Drug Regulatory Authority of Pakistan (DRAP) dossier submissions.
• Supply Chain Stability: Our localized API inventory management eliminates international transit variables. Whether you require a standard pilot batch or are scaling up a high-volume Fezolinetant api Pakistan procurement order, we help ensure that your commercial batch schedules and production timelines are met without line stoppages.
• Batch-to-Batch Uniformity: Every shipment coordinated by Morgan includes a detailed Certificate of Analysis (CoA) issued by the original manufacturer. We ensure our supplied batches maintain consistent chemical purity, controlled moisture limits, and a precise particle size distribution (PSD) for predictable behavior during blending, granulation, and tablet compression processes.

Technical Specifications for QA & R&D

The Fezolinetant API supplied by Morgan undergoes exacting analytical testing at the source to meet current international pharmacopeial standards.

• Chemical Name: (4-fluorophenyl)-(8-methyl-3-(3-methyl-1,2,4-thiadiazol-5-yl)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazin-7(8H)-yl)methanone
• CAS Number: 1629229-37-3
• Appearance: White to off-white crystalline solid powder
• Molecular Formula: C16H15FN6OS
• Molecular Weight: 358.39 g/mol
• Assay / Purity (HPLC): ≥ 99.0%
• Solubility Profile: Detailed solubility parameters across standard organic solvents and aqueous buffers of varying pH are documented in the technical data sheet to assist your analytical R&D teams with dissolution profiling and pre-formulation stability studies.

Manufacturing and Handling Guidelines for Formulators

Fezolinetant is a centrally acting pharmacological compound. Facilities processing this API must enforce strict occupational exposure limits (OEL) to protect personnel on the manufacturing floor.

• Storage Conditions: Store the raw API powder in securely closed, light-resistant containers. Maintain climate-controlled conditions as specified by the batch protocol (typically controlled room temperature, protected from excessive heat and humidity) to prevent chemical degradation and maintain structural integrity.
• Occupational Safety: Personnel handling the pure API powder must follow advanced industrial containment protocols. Processing requires appropriate Personal Protective Equipment (PPE), including P3/N95 industrial dust masks or respirators, chemical-resistant nitrile gloves, and full protective facility garments. Dispensing, milling, and blending stages must be executed within localized exhaust ventilation systems or dedicated negative-pressure containment isolators to prevent the inhalation of airborne particulates and cross-contamination.

Distributor Disclaimer: Morgan Chemicals is a pharmaceutical raw material trading and distribution company. This API is sourced from DRAP-registered, GMP-certified manufacturing partners. Morgan Chemicals does not manufacture APIs, does not hold DRAP manufacturing registration, and does not sell finished medicines. This product is supplied exclusively to licensed pharmaceutical companies, CMOs, and research facilities in Pakistan — not for individual or consumer sale.